North America Alzheimer’s Disease Drugs Market Analysis

North America Alzheimer’s Disease Drugs Market Executive Summary

The North America Alzheimer’s Disease Drugs market was valued at $7.71 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.42% from 2022 to 2030 and will reach $13.67 Bn in 2030. Alzheimer's disease is a progressive brain ailment that worsens with time. It is characterized by alterations in the brain that result in protein accumulation. Alzheimer's disease causes the brain to shrink and, eventually, brain cells to die. Alzheimer's disease is the most prevalent cause of dementia, which is characterized by a progressive decline in memory, thinking, behavior, and social skills. These alterations have an impact on a person's ability to operate.

Alzheimer's disease affects about 6 Mn Americans of all ages. In 2022, an estimated 6.5 Mn Americans aged 65 and up will have Alzheimer's disease. Seventy-three percent are 75 years old or older. Alzheimer's disease affects about one in every nine people aged 65 and up (10.7%). Women account for about two-thirds of Alzheimer's patients in the United States. Older Black Americans are roughly twice as likely as older Whites to have Alzheimer's or other dementias. As the number of elderly people increases, so will the number of new and current Alzheimer's cases. Without medical advances to prevent, halt, or cure Alzheimer's disease, the number of persons aged 65 and older with the condition is expected to rise to 12.7 Mn by 2050.

Market Dynamics

Market Growth Drivers

The increasing prevalence of Alzheimer's disease is one of the primary drivers of market growth. According to the Alzheimer's Association, an estimated 6.2 million Americans aged 65 and older have Alzheimer's disease, and this number is projected to increase to 12.7 Mn by 2050. This rising prevalence is expected to drive demand for Alzheimer's drugs in North America. The increasing aging population in North America is another significant driver of market growth. As per the United States Census Bureau, the population aged 65 and over in the United States is expected to reach 95 Mn by 2060, which is more than double the number in 2018. The aging population is expected to drive the demand for Alzheimer's drugs, as the disease is more common in older adults. The ongoing research and development in the field of Alzheimer's drugs are expected to drive market growth.

Several pharmaceutical companies are investing heavily in developing new drugs for Alzheimer's disease. For instance, Biogen's Aduhelm was granted accelerated approval by the FDA in June 2021, making it the first new Alzheimer's drug to be approved in nearly 20 years. This approval is expected to pave the way for other companies to develop new drugs for Alzheimer's disease. The regulatory environment in North America is favorable for Alzheimer's drugs, which is expected to drive market growth. The US FDA has granted several drugs fast-track designations, breakthrough therapy designations, and accelerated approvals in recent years, which has helped speed up the approval process for Alzheimer's drugs

Market Restraints

The cost of Alzheimer's drugs is high, which can make it difficult for some patients to access the treatment. According to a report by the Alzheimer's Association, the out-of-pocket cost of Alzheimer's drugs can be as high as $7,000 per year. This high cost can be a significant barrier to access for many patients, particularly those with limited financial resources. Alzheimer's disease can be difficult to diagnose, particularly in its early stages. This difficulty in diagnosis can lead to delays in treatment, which can worsen the progression of the disease. Improved diagnostic tools and techniques are needed to improve the accuracy of diagnosis and ensure that patients receive timely treatment.

Competitive Landscape

Key Players

• Amgen
• Eisai Co.
• Eli Lilly and Company
• Roche
• Johnson and Johnson
• Novartis AG
• Pfizer

Recent Updates

Jan 2023, the US Food and Drug Administration authorized Leqembi for the treatment of Alzheimer's disease through the Accelerated Approval process. Leqembi is the second of a new class of Alzheimer's disease drugs that target the illness's core pathogenesis.

Healthcare Policies and Regulatory Landscape

FDA is a federal agency of the US Department of Health and Human Services. It is responsible for regulating food, drugs, medical devices, and other products that affect public health. The FDA reviews and approves new drugs and medical devices conducts inspections of manufacturing facilities and monitors the safety and effectiveness of marketed products.

Centers for Medicare and Medicaid Services (CMS) is a federal agency that administers the Medicare and Medicaid programs in the United States. CMS is responsible for ensuring that the programs are administered in accordance with federal laws and regulations and that beneficiaries have access to high-quality, cost-effective healthcare services.

Health Canada is the federal department responsible for public health in Canada. Health Canada is responsible for regulating the safety, efficacy, and quality of drugs, medical devices, and other health products in Canada. The agency reviews and approves new products monitor safety and effectiveness and provides information and guidance to healthcare providers and patients.

Reimbursement Scenario

Medicare is a federal health insurance program for people aged 65 and older, and it covers some Alzheimer's drugs. However, coverage and reimbursement policies can vary depending on the FDA-approved drug and the patient's individual Medicare plan. Medicaid is a state-administered program that provides health insurance to low-income individuals and families. Like Medicare, coverage and reimbursement policies for Alzheimer's drugs can vary depending on the specific drug and the state in which the patient resides. Some states may have coverage limits or require prior authorization for certain drugs.